Reimbursement of orphan drugs in Belgium: what (else) matters?

Reimbursement of orphan drugs in Belgium: what (else) matters?. Eline Picavet, David Cassiman and Steven Simoens; Orphanet Journal of Rare Diseases 2014, 9:139 doi:10.1186/s13023-014-0139-z

Excellent analysis of the problem, although the study focuses on the problem of orphan drugs in e Belgium, the findings can be extrapolated to most countries.

OPEN ACCESS, FULL TEXT PDF